APNHY
Aspen Pharmacare Holdings Limited, together with its subsidiaries, manufactures and supplies specialty and branded pharmaceutical products worldwide. It operates in Commercial Pharmaceuticals and Manufacturing segments. The company provides general anesthetics, muscle relaxants, and topical agents under the Anaesthetics brand; and a range of injectable anticoagulants with a focus on low molecular weight heparins, Xa inhibitors, and heparin derivatives under the Thrombosis brand. It also offers branded consumer, prescription, and over-the-counter products under the regional brands, such as Circadin, Foxair, Maltofer, Mybulen, and Zyloric for various types of anesthetic comprises sleeping aid, respiratory, iron supplement, analgesic, and uric acid production inhibitor. In addition, the company manufactures and sells active pharmaceutical ingredients and finished dose form products to third-party customers. The company was founded in 1850 and is headquartered in Durban, South Africa.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | 3.15 | $16.3B | $2.3B |
| 2025 Q4 | -7.82 | $21.4B | $2.0B |
| 2024 Q2 | 5.38 | $22.0B | $608M |
| 2024 Q4 | 4.71 | $23.6B | $2.1B |
| 2023 Q2 | 5.21 | $21.1B | $966M |
| 2023 Q4 | 5.75 | $21.6B | $1.8B |
| 2022 Q2 | 6.02 | $19.1B | $587M |
| 2022 Q4 | 6.94 | $19.2B | $2.0B |